Immune checkpoint inhibitors (ICIs) have been widely used in the treatment of non-small cell lung cancer (NSCLC) . However, ICIs related pneumonia, myocarditis, rash, colitis, nervous system immune-related adverse events (irAEs) , as well as hypothyroidism, ocular irAEs, liver irAEs, etc., can be generated in the process of use, and some irAEs are even fatal. Systemic inflammatory biomarkers as well as chemotherapy, higher body mass index, epidermal growth factor receptor mutation are risk factors for its occurrence. The common irAEs and risk factors are analyzed in order to improve the clinician's understanding of ICIs.